

NCI

FACT BOOK

**National
Cancer
Institute**

2004

**U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES**

Public Health Service

National Institutes of Health

The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892.

TABLE OF CONTENTS

Executive Summary	Fiscal Year 2004 Annual Report..... iii
Organization	Director's Biography O-1 Former Directors of the NCI O-2 National Cancer Advisory Board..... O-3 Boards of Scientific Counselors and Advisors O-7 President's Cancer Panel O-8 Executive Committee Members..... O-8 NCI Director's Consumer Liaison Group..... O-9 Organization Charts: National Cancer Institute O-10 Office of the Director O-11 OD I: Office of Management..... O-12 OD II: Office of the Deputy Director O-13 OD II: Center for Strategic Scientific Initiatives O-13 OD II: Center for Strategic Dissemination O-13 OD III: Office of the Deputy Director for Extramural Science.. O-14 OD IV: Center to Reduce Cancer Health Disparities..... O-15 OD IV: Office of Budget and Financial Management..... O-15 OD IV: Office of Science Planning and Assessment..... O-15 OD IV: Office of Communication..... O-15 Center for Cancer Research..... O-16 Division of Cancer Epidemiology and Genetics O-18 Division of Cancer Prevention O-19 Division of Cancer Control and Population Sciences O-20 Division of Cancer Treatment and Diagnosis..... O-21 Division of Cancer Biology..... O-22 Division of Extramural Activities..... O-23
Cancer Statistics	Number of Deaths for the Five Leading Cancer Sites..... C-1 Relationship of Cancer to the Leading Causes of Death in the U.S.. C-1 Estimated New Cancer Cases and Deaths..... C-2 The Cost of Cancer C-3 Average Years of Life Lost Per Person Dying of Cancer C-4 Five-Year Relative Survival Rates by Cancer Site..... C-5 Cancer Incidence Rates C-6 Cancer Mortality Rates Changes from 1992 to 2002 C-7 Cancer Incidence Rates by Race C-8 Cancer Mortality Rates by Race C-9 The Prevalence of Cancer C-10
Budget Data	NCI Budget..... B-1 Program Structure..... B-2 Extramural Funds B-3 NCI Obligations by Mechanism B-4 Division Obligations by Mechanism B-5 NIH Management Fund, Service & Supply Fund and GSA Rent... B-6 Special Sources of Funds..... B-7

Extramural Programs	Funding for Various Research Areas.....	B-8
	Research Project Grants:	
	Number of Awards.....	E-1
	Requested, Awarded.....	E-2
	Awards by Activity Code.....	E-3
	Activity Code Descriptions.....	E-4
	Cancer Centers	
	By State.....	E-5
	Specialized Programs of Research Excellence (SPORE).....	E-6
	National Research Service Awards – Pre and Post Doctoral Trainees.....	E-7
	Construction/Renovation Funding.....	E-8
	Grant and Contract Awards by State.....	E-9
	Grant and Contract Awards by Country.....	E-10
	Institutions Receiving More than \$15,000,000 in NCI Support....	E-11
Historical Trends	Appropriations of the NCI.....	H-1
	Bypass Budget Requests.....	H-2
	Comparison of Bypass Requests and Appropriations of the NCI.....	H-3
	Comparison of Dollars, Positions and Space.....	H-4
	Personnel Resources.....	H-5
	AIDS Funding History.....	H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Financial Management Branch homepage on the National Cancer Institute's website: www.nci.nih.gov or www.cancer.gov.

National Cancer Institute

Director's Biography

Andrew C. von Eschenbach, M.D.

Andrew C. von Eschenbach, M.D. is the 12th Director in the 67 year history of the National Cancer Institute. He is a nationally recognized urologic surgeon who formerly directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as special assistant for external affairs to M.D. Anderson's president and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.

A native of Philadelphia, Dr. von Eschenbach received his medical degree from Georgetown University Medical School in 1967. He completed residencies in general surgery and urology at Pennsylvania Hospital in Philadelphia, then was an instructor in urology at the University of Pennsylvania School of Medicine. He served as a Lieutenant Commander in the U.S. Navy Medical Corps.

In 1976, Dr. von Eschenbach went to M.D. Anderson Cancer Center for a fellowship in urologic oncology and was invited to join the faculty the following year. From 1983 to 1996, he was Chairman of the Department of Urology and, since 1985, has also been a Consulting Professor in the Department of Cancer Biology.

In 1996, Dr. von Eschenbach was named the founding director of M.D. Anderson's Prostate Cancer Research Program, comprised of over 60 scientists and clinicians collaborating on integrated translational research in the biology, treatment, epidemiology and prevention of the disease. From 1997 to 1999, he also served as Vice President for Academic Affairs and then as Executive Vice President and Chief Academic Officer, leading a faculty of almost 1,000 cancer researchers and clinicians.

He was a founding member of C-Change and, prior to his accepting the position as NCI Director, he was President-elect of the American Cancer Society. Dr. von Eschenbach has contributed more than 200 articles, books and chapters to the scientific literature.

Former Directors of the National Cancer Institute

Richard D. Klausner, M.D.

August 1995 – September 2001

Dr. Klausner was appointed as the Director of the National Cancer Institute (NCI) on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development. Dr. Klausner is well known for his contributions to multiple aspects of cell and molecular biology. Dr. Klausner's research has illuminated the genetics and biochemistry of metals as essential but toxic nutrients for virtually all forms of life, has illuminated the pathways by which molecules traffic and speak to each other within the cell, and has described novel mechanisms by which tumor suppressor genes function.

Samuel Broder, M.D.

December 1988 – March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program. In 1985 he led the laboratory team that discovered the therapeutic effects of AZT and other drugs now approved for the treatment of AIDS including DDI and DDC.

Vincent T. DeVita, Jr., M.D.

January 1980 – June 1980 (Acting)
July 1980 – August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

Arthur Canfield Upton, M.D.

July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

Frank Joseph Rauscher, Jr., Ph.D.

May 1972 – October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

Carl Gwin Baker, M.D.

November 1969 – July 1970 (Acting)
July 1970 – April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

Kenneth Milo Endicott, M.D.

July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

John Roderick Heller, M.D.

May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Leonard Andrew Scheele, M.D.

July 1947 – April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

Roscoe Roy Spencer, M.D.

August 1943 – July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

Carl Voegtlin, Ph.D.

January 1938 – July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

National Cancer Advisory Board

Membership and Term

2006 Chairperson

John E. Niederhuber, M.D.

University of Wisconsin School of Medicine
Madison, WI 53792

2006 Eric S. Lander, Ph.D.

The Broad Institute of MIT and Harvard
MIT and Harvard Medical School
The Whitehead Institute for Biomedical Research
Cambridge, MA 02141

2006 Samir Abu-Ghazaleh, M.D.

Avera Cancer Institute
Sioux Falls, SD 57105

2010 Diana M. Lopez, Ph.D.

Department of Microbiology & Immunology
University of Miami School of Medicine
Miami, FL 33136

2006 James O. Armitage, M.D.

College of Medicine
University of Nebraska Medical Center
Omaha, NE 68198

2006 Arthur W. Nienhuis, M.D.

St. Jude Children's Research Hospital
Memphis, TN 38101

2008 Moon Shao-Chuang Chen, Jr., Ph.D., M.P.H.

University of California
Davis Cancer Center
Sacramento, CA 95817

2008 Ms. Marlys Popma

HIS Consulting
Des Moines, IA 50309

2008 Kenneth H. Cowan, M.D., Ph.D.

University of Nebraska Medical Center
Eppley Institute for Cancer Research
Omaha, NE 68198

2008 Franklyn G. Prendergast, M.D., Ph.D.

Mayo Clinic Cancer Center
Mayo Foundation
Rochester, MN 55905

2008 Jean B. deKernion, M.D.

Department of Urology
UCLA School of Medicine
Los Angeles, CA 90095

2010 Carolyn D. Runowicz, M.D.

The Carol and Ray Neag Comprehensive
Cancer Center
University of Connecticut Health Center
Farmington, CT 06030

2006 Ralph S. Freedman, M.B.B.Ch., Ph.D.

Department of Gynecologic Oncology
University of Texas
Houston, TX 77030

2008 Lydia G. Ryan, M.S.N., P.N.P.

Children's Healthcare of Atlanta
AFLAC Cancer Center
Atlanta, GA 30322

2006 James H. French, M.D.

The Center for Plastic Surgery
Annandale, VA 22003

2010 Daniel D. Von Hoff, M.D., F.A.C.P.

Translational Genomics Research Institute
Phoenix, AZ 85004

2010 Kathryn Giusti, M.B.A.

Multiple Myeloma Research Foundation, Inc.
New Canaan, CT 06840

Executive Secretary

Paulette S. Gray, Ph.D.

2010 David H. Koch

Koch Industries
New York, NY 10021

Committee Management Officer

Ms. Claire L. Harris

National Cancer Advisory Board (Continued)

Ex Officio Members

The Honorable Elaine Chao, M.B.A.

Secretary of Labor
Washington, DC 20210

Lester M. Crawford, D.V.M., Ph.D.

Acting Commissioner
Food and Drug Administration
Rockville, MD 20857

John Howard, M.D., M.P.H., J.D., LL.M.

National Institute for Occupational Safety and Health (NIOSH)
Washington, DC 20857

Mr. Stephen L. Johnson

Administrator
Environmental Protection Agency
Washington, DC

The Honorable Mr. Michael O. Leavitt

Secretary
Department of Health and Human Services
Washington, DC 20201

Rachel Levinson

Assistant Director for Life Sciences
Office of Science and Technology Policy
Washington, DC 20502

Ari Patrinos, Ph.D.

Associate Director
Office of Biological and Environmental Research
U.S. Department of Energy
Washington, DC 20585

The Honorable Dr. Jonathan Perlin

Under Secretary for Health
Veterans Health Administration
Department of Veterans Affairs
Washington, DC 20420

David A. Schwartz, M.D.

National Institute of Environmental Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709

Mr. Hal Stratton

Chairman
Consumer Product Safety Commission
Bethesda, MD 20814

The Honorable Dr. William Windwerder, Jr.

Assistant Secretary of Defense for Health Affairs
Washington, DC 20301-1200

Elias A. Zerhouni, M.D.

Director
National Institutes of Health
Bethesda, MD 20892

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Michael A. Babich, Ph.D.
Directorate for Health Sciences
U.S. Consumer Product Safety Commission
Bethesda, MD 20814
(Mr. Hal Stratton - CPSC)

Allen Dearry, Ph.D.
Associate Director for Research
Coordination
Division of Intramural Research
National Institute of Environmental Health
Sciences
National Institutes of Health
Research Triangle Park, NC 27709
(David A. Schwartz, M.D. -NIEHS)

Raynard Kington, M.D., Ph.D.
Deputy Director
National Institutes of Health
Bethesda, MD 20892
(Elias A. Zerhouni, M.D., - NIH)

Peter Kirchner, M.D.
Program Manager
Office of Biological & Environmental Research
Division of Medical Science
U.S. Department of Energy
Germantown, MD 20874-1290
(Ari Patrinos, Ph.D. - DOE)

T. G. Patel, M.D., M.A.C.P.
Captain MC USN (Retired)
Program Chief
Veterans Health Administration
Department of Veterans' Affairs
Washington, DC 20420
(The Honorable Dr. Jonathan B. Perlin - VA)

Richard Pazdur, M.D.
Division Director
Division of Oncology Drugs
Food and Drug Administration
Rockville, MD 20857
(Lester M. Crawford, D.V.M., Ph.D. - FDA)

John F. Potter, M.D.
Director
United States Military Cancer Institute
Walter Reed Army Medical Center
Washington D.C. 20307
(The Honorable Dr. William Winkwerder, Jr. - DOD)

R. Julian Preston, Ph.D.
Director
Environmental Carcinogenesis Division
U.S. Environmental Protection Agency
Research Triangle Park, NC 27703
(Steven L. Johnson, Acting Administrator - EPA)

Anita L. Schill, Ph.D., M.P.H., M.A., R.N., COHN-S
Senior Scientist
Office of the Director
National Institute for Occupational Safety
and Health
Washington, DC 20201
(John Howard, M.D., M.P.H., J.D., LL.M. - NIOSH)

Donald J. Wright, M.D. MPH
Director
Office of Occupational Medicine
Department of Labor, OSHA
Washington, DC 20210
(The Honorable Elaine Chao - DOL)

Note: Bold print represents Ex Officio Members

National Cancer Advisory Board (Continued)

NCAB Subcommittee Assignments

Subcommittee on Activities and Agenda

Dr. John Niederhuber - Chair
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Jean B. deKernion
Dr. Ralph S. Freedman
Ms. Lydia Ryan
Ms. Marlys Popma
Dr. R. Julian Preston, EPA
Dr. Donald Wright, DOL
EXECUTIVE SECRETARY: Dr. Cedric Long
(301) 496-9138

Subcommittee on Cancer Centers

Dr. Arthur W. Nienhuis - Chair
Dr. Kenneth Cowan
Dr. Samir Abu-Ghazaleh
Dr. Carolyn Runowicz
Mr. David Koch
Dr. Allen Dearry, NIEHS
EXECUTIVE SECRETARY: Dr. Karen Antman
(301) 496-6511

Subcommittee on Clinical Investigations

Dr. Jean B. deKernion - Chair
Dr. Daniel Von Hoff
Ms. Kathryn Giusti
Mr. David Koch
Dr. Ralph S. Freedman
Dr. James Armitage
Dr. Richard Padzur, FDA
Dr. John Potter, DOD
EXECUTIVE SECRETARY: Dr. James Doroshow
(301) 496-4291

Subcommittee on Planning and Budget

Dr. Franklyn Prendergast - Chair
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Eric Lander
Dr. Dianan Lopez
Ms. Marlys Popma
EXECUTIVE SECRETARY: Ms. Cherie Nichols
(301) 496-5515

Subcommittee on Special Actions

Dr. Ralph Freedman - Chair
Committee of the Whole
EXECUTIVE SECRETARY: Dr. Paulette Gray
(301) 496-4218

Ad hoc Subcommittee on Communications

Ms. Lydia Ryan - Chair
Dr. Samir Abu-Ghazaleh
Ms. Kathryn Giusti
Dr. Diana Lopez
Ms. Marlys Popma
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Michael Babich, CPSC
Dr. Allen Dearry, NIEHS
Dr. Anita Schill, NIOSH
EXECUTIVE SECRETARY: Ms. Nelvis Castro
(301) 435-7778

Ad hoc Subcommittee on Confidentiality of Patient Data

Dr. Kenneth Cowan - Chair
Ms. Lydia Ryan
Dr. Ralph S. Freedman
Dr. Carolyn Runowicz
Dr. James Armitage
Dr. Peter Kirchner, DOE
Dr. T. G. Patel, VA
EXECUTIVE SECRETARY: Dr. Roger Aamodt
(301) 496-7147

Ad hoc Subcommittee on Biomedical Technology

Dr. Eric Lander - Chair
Dr. Daniel Von Hoff
Ms. Kathryn Giusti
Dr. Ralph Freedman
Dr. John Niederhuber
Mr. David Koch
EXECUTIVE SECRETARY: Ms. Kathleen Schlom
(301) 435-5709

Board of Scientific Counselors Intramural Programs

Subcommittee 1: Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Chair - Margaret Tempero, M.D.	2006		
Leslie Bernstein, Ph.D.	2006	Richard J. O'Reilly, M.D.	2005
Esteban Celis, M.D., Ph.D.	2008	Andrew Olshan, Ph.D.	2009
Leland Chung, Ph.D.	2008	Alice P. Pentland, M.D.	2005
Chi Van Dang, M.D., Ph.D.	2005	Arthur T. Porter, M.D.	2005
Elizabeth T. Fontham, DrPH	2005	Timothy Rebbeck, Ph.D.	2009
Barbara Gilchrest, M.D.	2009	Eric Rowinsky, M.D.	2008
Stanley R. Hamilton, M.D.	2006	Charles Sawyers, M.D.	2009
Laurence N. Kolonel, M.D., Ph.D.	2005	David T. Scadden, M.D.	2007
Bruce Korf, M.D., Ph.D.	2008	Steven G. Self, Ph.D.	2006
Theodore Lawrence, M.D., Ph.D.	2009	Paul Sondel, M.D., Ph.D.	2009
Susan Leigh, RN	2008	Michael Thun, M.D.	2005
Susan Mayne, Ph.D.	2009		
Daniel M. Medina, Ph.D.	2006		
		Executive Secretary - Abby B. Sandler, Ph.D.	

Subcommittee 2: Basic Sciences

Chair - Frederick Alt, Ph.D.	2005		
Sankar Ghosh, Ph.D.	2006	Martine Roussel, Ph.D.	2008
Michael Gould, Ph.D.	2009	Robert Siliciano, M.D., Ph.D.	2009
Katherine Jones, Ph.D.	2008	Harinder Singh, Ph.D.	2007
Richard D. Kolodner, Ph.D.	2005	Ronald I. Swanson, Ph.D.	2006
John Kuriyan, Ph.D.	2005	Thea D. Tlsty, Ph.D.	2006
Laimonis Laimins, Ph.D.	2009	Jeffrey Trent, Ph.D.	2009
Dan R. Littman, M.D., Ph.D.	2007	Cheryl Lyn Walker, Ph.D.	2006
Guillermina Lozano, Ph.D.	2007	Eileen White, Ph.D.	2005
Brooke T. Mossman, Ph.D.	2005	Jerry Workman, Ph.D.	2009
Dinshaw J. Patel, Ph.D.	2005		
		Executive Secretary - Florence E. Farber, Ph.D.	

Board of Scientific Advisors Extramural Programs

Chair - Robert C. Young	2007		
David B. Abrams, Ph.D.	2006	Kenneth W. Kinzler, Ph.D.	2006
David S. Alberts, M.D.	2006	Michael P. Link, M.D.	2007
Hoda A. Anton-Culver, Ph.D.	2006	Christopher J. Logothetis, M.D.	2009
Kriby I. Bland, M.D.	2009	Lynn M. Matrisian, Ph.D.	2007
Esther H. Chang, Ph.D.	2006	Christine A. Miasowski, Ph.D.	2005
Neil J. Clendeninn, M.D., Ph.D.	2005	Edith A. Perez, M.D.	2009
Thomas M. Curran, Ph.D.	2005	John D. Potter, M.D., Ph.D.	2009
Raymond N. Dubois, M.D., Ph.D.	2007	Mack Roach III, M.D.	2007
H. Shelton Earp III, M.D.	2007	Richard L. Schilsky, M.D.	2006
Kathleen M. Foley, M.D.	2009	Ellen V. Sigal, Ph.D.	2009
Sanjiv S. Gambhir, M.D., Ph.D.	2009	Margaret R. Spitz, M.D., M.P.H.	2007
Patricia A. Ganz, M.D.	2007	Jane C. Weeks, M.D.	2009
Joe W. Gray, Ph.D.	2009		
William N. Hait, M.D., Ph.D.	2008		
Mary J. Hendrix, Ph.D.	2009		
Leroy E. Hood, Ph.D., M.D.	2009		
Susan B. Horwitz, Ph.D.	2006		
Hedvig Hricak, M.D., Ph.D.	2007		
Eric Hunter, Ph.D.	2007	Executive Secretary - Paulette S. Gray, Ph.D.	
William G. Kaelin, M.D.	2005		
Paula K. Kim	2007		

President's Cancer Panel

LaSalle D. Leffall, Jr. M.D., F.A.C.S. 2007

Chairman
Charles R. Drew Professor of Surgery
Howard University Hospital
2041 Georgia Avenue, NW
Suite 4000
Washington, DC 20060

Margaret Kripke, Ph.D. 2006

Executive Vice President/Chief Academics Officer
University of Texas
M.D. Anderson Cancer Center
Unit 113
1515 Holcombe Boulevard
Houston, TX 77030

Lance E. Armstrong 2005

Founder, Lance Armstrong Foundation
2901 Bee Caves Road
Suite L
Austin, TX 78746

Maureen O. Wilson, Ph.D.

Executive Secretary

Executive Committee Members

Andrew C. von Eschenbach, M.D.

Director

Alan Rabson, M.D.

Deputy Director

Karen Antman, M.D.

Deputy Director, Clinical and Translational Sciences

Anna Barker, Ph.D.

Deputy Director, Advanced Technologies and
Strategic Partnerships

J. Carl Barrett, Ph. D.

Director, Center for Cancer Research

Mark Clanton, M.D., M. P.H.

Deputy Director, Cancer Care Delivery Systems

Robert Croyle, Ph. D.

Director, Division of Cancer Control and
Population Sciences

James Doroshow, M.D.

Director, Division of Cancer Treatment
and Diagnosis

David A. Elizalde, J.D., LL.M.

Deputy Director for Management

Joseph Fraumeni, M.D.

Director, Division of Cancer Epidemiology and
Genetics

Harold P. Freeman, M.D.

Director, Center to Reduce Cancer Health
Disparities

Paulette Gray, Ph. D.

Acting Director, Division of Extramural Activities

Peter Greenwald, M.D.

Director, Division of Cancer Prevention

John Hartinger

Associate Director for Budget and Financial
Management

Ernest T. Hawk, M.D., M.P.H.

Director, Office of Centers, Training, & Resources

Dinah Singer, Ph. D.

Director, Division of Cancer Biology

Sandy Koeneman, M.S., M.P.A.


Executive Secretary


NCI Director's Consumer Liaison Group

Mr. Doug Ulman, Chair Lance Armstrong Foundation	2008	Dr. Sylvia Ramos People Living Through Cancer/Intercultural Cancer Council	2006
Ms. Margaret L. Anthony Yul Brynner Head and Neck Foundation	2006	Mr. Eric Rosenthal EvocaTalk® Reports	2006
Ms. Vernal H. Branch Virginia Breast Cancer Foundation/ National Breast Cancer Coalition	2007	Ms. Mary Jackson Scroggins Ovarian Cancer National Alliance	2007
Mr. William Bro Kidney Cancer Association	2008	Ms. Sue Sumpter Leukemia & Lymphoma Society/Candlelighters Childhood Cancer Foundation	2007
Ms. Lourie Campos Community Health Partnership	2008	Dr. Marisa Weiss breastcancer.org	2007
Ms. Nancy Davenport-Ennis Patient Advocate Foundation	2008	Ms. Celeste Whitewolf Native People's Circle of Hope	2006
Ms. Bobbi de Córdoba Hanks Bosom Buddies/Women's Center of Jacksonville	2006	Col. (Ret.) James Williams Pennsylvania Prostate Cancer Coalition	2008
Dr. Beverly Laird American Cancer Society/Komen Breast Cancer Foundation	2007		

Ms. Nancy Caliman, Executive Secretary
 Director's Consumer Liaison Group
 Office of Liaison Activities
 National Cancer Institute
 6116 Executive Boulevard, Suite 220
 Bethesda, MD 20892


National Cancer Institute





Office of the Director Continued - OD I


Office of Management
Deputy Director
Mr. David Elizalde
301-435-2455




Office of the Deputy Director
Deputy Director
Dr. Alan Rabson
301-496-1927





Center for Strategic Scientific Initiatives
Deputy Director for Advanced Technology and Strategic Partnerships
Dr. Anna Barker
301-496-1550



Center for Strategic Dissemination
Director
Vacant
Deputy Director
Ms. Jill Bartholomew
301-451-1368







**Center for Cancer Research
Office of the Director**

Director
Dr. J. Carl Barrett
301-496-4345

Principal Deputy Director
Dr. Robert Wiltrott
301-846-1258

Laboratory of Cancer Prevention
Chief
Dr. Nancy Colburn
301-496-6874

Laboratory of Mammary Biology & Tumorigenesis
Chief
Dr. Barbara Vonderhaar
301-594-9940

Laboratory of Immunobiology
Chief
Dr. Bert Zbar
301-846-1557

Laboratory of Tumor Immunology and Biology
Chief
Dr. Jeffrey Schlom
301-496-4343

Laboratory of Experimental Carcinogenesis
Chief
Dr. Snorri Thorgeirsson
301-496-1935

Laboratory of Biochemistry
Chief
Dr. Michael Lichten
301-496-5957

Laboratory of Cellular and Molecular Biology
Chief
Dr. Larry Samelson
301-496-9683

Laboratory of Genetics
Chief
Dr. Beverly Mock
301-496-1734

Laboratory of Molecular Biology
Chief
Dr. Ira Pastan
301-496-4797

Mouse Cancer Genetics Program
Chief
Dr. Neal G. Copeland
301-846-1260

Laboratory of Comparative Carcinogenesis
Chief
Dr. Larry Keefer
301-846-1467

Laboratory of Molecular Cell Biology
Chief
Dr. Carl Wu
301-496-3029

Laboratory of Cellular Carcinogenesis and Tumor Promotion
Chief
Dr. Stuart Yuspa
301-496-2162

Laboratory of Experimental and Computational Biology
Chief
Dr. Jacob Maizel
301-846-5532

Surgery Branch
Chief
Dr. Steven Rosenberg
301-496-4164

Cancer and Developmental Biology Laboratory
Chief
Dr. Colin Stewart
301-846-1755

Laboratory of Pathology
Chief
Dr. Lance Liotta
301-496-3185

Laboratory of Molecular Pharmacology
Chief
Dr. Yves Pommier
301-496-5944

Molecular Targets Drug Development Program
Chief
Dr. James McMahon
301-846-5391

Experimental Transplantational and Immunology Branch
Chief
Dr. Ronald Gress
301-496-6898

Genetics Branch
Chief
Dr. Ilan Kirsch
301-496-0901

Neuro-Oncology Branch
Chief
Dr. Howard Fine
301-435-4024

Metabolism Branch
Chief
Dr. Thomas Waldmann
301-496-6653

Cancer Therapeutics Branch
Chief
Dr. Sandra Swain
301-496-4916

Urologic Oncology Branch
Chief
Dr. W. Marston Linehan
301-496-6353

Laboratory of Population Genetics
Chief
Dr. Kenneth Buetow
301-435-8953

**Center for Cancer Research
Office of the Director**

Director
Dr. J. Carl Barrett
301-496-4345

Principal Deputy Director
Dr. Robert Wiltout
301-496-4346

Vaccine Branch
Chief
Dr. Jay Berzofsky
301-496-6824

Laboratory of Retroviral
Replication
Chief
Dr. Stephen Hughes
301-846-1180

Laboratory of Cellular Oncology
Chief
Dr. Douglas Lowy
301-496-9513

Laboratory of Genomic Diversity
Chief
Dr. Stephen O'Brien
301-846-1296

Laboratory of Medicinal
Chemistry
Chief
Dr. Victor Marquez
301-846-5954

Laboratory of Receptor Biology
and Gene Expression
Chief
Dr. Gordon Hager
301-496-9867

Laboratory of Metabolism
Chief
Dr. Frank Gonzalez
301-435-5587

Experimental Immunology
Branch
Chief
Dr. Alfred Singer
301-496-5461

Laboratory of Cell Regulation
and Carcinogenesis
Chief
Dr. Glenn Merlino
301-496-4270

Laboratory of Immune Cell
Biology
Chief
Dr. Jonathan Ashwell
301-496-4931

Basic Research Laboratory
Chiefs
Dr. Robert Wiltout
301-846-1258
Dr. Douglas Lowy
301-496-9513

Laboratory of Experimental
Immunology
Chief
Dr. John Ortaldo
301-846-1323

Structural Biophysics
Laboratory
Chief
Dr. R. Andrew Byrd
301-846-1407

Laboratory of Cell Biology
Chief
Dr. Michael Gottesman
301-496-1530

HIV Drug Resistance Program
Chief
Dr. John Coffin
301-846-5943

Laboratory of Molecular
Immunoregulation
Chief
Dr. Joost Oppenheim
301-846-1551

Laboratory of Human
Carcinogenesis
Chief
Dr. Curtis Harris
301-496-2048

Dermatology Branch
Chief
Dr. Mark Udey
301-496-1741

Pediatric Oncology Branch
Chief
Dr. Lee Helman
301-496-4257

Cell and Cancer Biology Branch
Chief
Dr. Kathleen Kelly
301-435-4651

Laboratory of Protein Dynamics
and Signaling
Chief
Dr. Allan Weissman
301-846-1222

Gene Regulation and
Chromosome Biology
Laboratory
Chief
Dr. Jeffrey N. Strathern
301-846-1274

Medical Oncology Clinical
Research Branch
Acting Chief
Dr. Ronald Gress
301-496-1791

Laboratory of Resistance
Mechanisms
Chief
Dr. Stuart LeGrice
301-846-5943

Radiation Oncology Branch
Chief
Dr. C. Norman Coleman
301-496-5457


Radiation Biology Branch
Chief
Dr. James Mitchell
301-496-7511

Macromolecular Crystallography
Laboratory
Chief
Dr. Alexander Wlodawer
301-846-5036

Laboratory of Biosystems and
Cancer
Chief
Dr. J. Carl Barrett
301-594-8466

HIV and AIDS Malignancy
Branch
Chief
Dr. Robert Yarchoan
301-496-0328

Molecular Imaging Program
Chief
Dr. Peter Choyke
301-451-6039



**Division of Cancer Prevention
Office of the Director**

Director
Dr. Peter Greenwald
301-496-6616

Acting Deputy Director
Dr. Leslie Ford
301-496-0265

Associate Director for Clinical Research
Dr. Leslie Ford
301-496-0265

Office of Preventive Oncology
Chief
Dr. Douglas Weed
301-496-8640

**Chemoprevention Agent
Development Research Group**
Chief
Dr. James Crowell
301-496-8563

**Community Oncology and
Prevention Trials Research
Group**
Chief
Dr. Lori Minasian
301-496-8541

**Breast & Gynecologic Cancer
Research Group**
Chief
Dr. Karen Johnson
301-496-8526

**Prostate & Urologic Cancer
Research Group**
Chief
Dr. Howard Parnes
301-594-0920

**Early Detection
Research Group**
Chief
Dr. Christine Berg
301-496-8544

**Biometry Research
Group**
Chief
Dr. Phillip Prorok
301-496-8556


**Gastrointestinal & Other Cancer
Research Group**
Acting Chief
Dr. Jaye Viner
301-594-2684

**Lung & Upper Aerodigestive
Cancer Research Group**
Chief
Dr. Eva Szabo
301-435-1595

**Nutritional Science
Research Group**
Chief
Dr. John Milner
301-496-8573

**Basic Prevention Science
Research Group**
Acting Chief
Dr. John Gohagan
301-496-3982

**Cancer Biomarkers
Research Group**
Chief
Dr. Sudhir Srivastava
301-435-1594



**Division of Cancer Treatment and Diagnosis
Office of the Director**

Director
Dr. James H. Doroshow
301-496-4291
Deputy Director
Vacant
301-496-6711

Biometrics Research Branch
Chief
Dr. Richard Simon
301-496-4836

Radiation Research Program
Associate Director
Dr. Norman Coleman
301-496-6111

Radiotherapy Development Branch
Chief
Dr. Francis Mahoney
301-496-9360

Molecular Therapeutics Branch
Chief
Dr. Philip Tofilon
301-496-6336

Clinical Radiation Oncology Branch
Chief
Vacant
301-496-6111

Cancer Therapy Evaluation Program
Associate Director
Dr. Michael Christian
301-496-6138

Investigational Drug Branch
Acting Chief
Dr. Anthony Murgo
301-496-1196

Clinical Investigations Branch
Chief
Dr. Jeffrey Abrams
301-496-2522

Pharmaceutical Management Branch
Chief
Mr. Charles Hall
301-496-5725

Regulatory Affairs Branch
Chief
Dr. Dale Shoemaker
301-496-7912

Clinical Trials Monitoring Branch
Chief
Ms. Joan Mauer
301-496-0510

Clinical Grants and Contracts Branch
Chief
Dr. Roy Wu
301-496-8866

Developmental Therapeutics Program
Acting Associate Director
Dr. Joseph Tomaszewski
301-496-8777
Deputy Associate Director
Vacant

Information Technology Branch
Chief
Dr. Dan Zaharevitz
301-496-8747

Biological Testing Branch
Chief
Dr. Joseph Mayo
301-846-5065

Biological Resources Branch
Chief
Dr. Stephen Creekmore
301-846-1098

Toxicology and Pharmacology Branch
Chief
Dr. Joseph Tomaszewski
301-496-8777

Screening Technologies Branch
Chief
Dr. Robert Shoemaker
301-846-1064

Natural Products Branch
Chief
Dr. Gordon Cragg
301-846-5387

Drug Synthesis and Chemistry Branch
Chief
Dr. Ven Narayanan
301-496-8795

Grants and Contracts Operations Branch
Chief
Dr. Mary Wolpert-DeFilippes
301-496-8783

Pharmaceutical Resources Branch
Chief
Dr. Rao Vishnuvajjala
301-496-8780

Cancer Diagnosis Program
Associate Director
Dr. Sheila Taube
301-496-8639

Diagnostics Evaluation Branch
Chief
Vacant

Resources Development Branch
Chief
Dr. Roger Aamodt
301-496-7147

Diagnostic Biomarkers and Technology Branch
Chief
Dr. James Jacobson
301-402-4185

Cancer Imaging Program
Associate Director
Dr. Daniel Sullivan
301-496-9531

Diagnostic Imaging Branch
Chief
Vacant

Molecular Imaging Branch
Chief
Dr. John Hoffman
301-496-9531

Image-Guided Intervention Branch
Chief
Dr. Gary Becker
301-496-9531

Imaging Technology Development Branch
Chief
Dr. Laurence Clarke
301-496-9531

**Division of Cancer Biology
Office of the Director**

Director
Dr. Dinah S. Singer
301-496-8636

Deputy Director
Dr. John A. Sogn
301-496-8636

Cancer Etiology Branch
Chief
Dr. Jack Gruber
301-496-9740

**Tumor Biology and Metastasis
Branch**
Chief
Dr. Suresh Mohla
301-435-1878

**Cancer Immunology and Hematology
Branch**
Chief
Dr. R. Allan Mufson
301-496-7815

**DNA and Chromosome Aberrations
Branch**
Chief
Dr. Judith Mietz
301-496-9326

Cancer Cell Biology Branch
Chief
Dr. Barbara Spalholz
301-496-7028

**Structural Biology and Molecular
Applications Branch**
Chief
Dr. Daniel Gallahan
301-435-5226

**Division of Extramural
Activities**

Acting Director
Dr. Paulette S. Gray
301-496-5147

Deputy Director
Dr. Paulette S. Gray
301-496-5147

Assistant Director
Dr. Cedric W. Long
301-496-9138

**Office of Extramural
Applications**

Associate Director
Dr. Paulette S. Gray
301-496-5147

**Office of Referral, Review and
Program Coordination**

Associate Director
Ms. Diane Bronzert
301-435-5655

**Applied Information
Systems Branch**

Chief
Mr. James W. Seach
301-496-7047

**Research Analysis and
Evaluation Branch**

Chief
Ms. Marilyn Gaston
301-594-1111

**Research Programs
Review Branch**

Chief
Dr. Olivia T. Bartlett
301-594-2501

**Special Review and
Logistics Branch**

Chief
Dr. Kirt J. Vener
301-496-7174

**Program Coordination and
Referral Branch**

Chief
Dr. Christopher Hatch
301-594-1403

**Resources and Training
Review Branch**

Chief
Dr. David Maslow
301-496-2330

Number of Deaths for the Five Leading Cancer Sites by Age Group and Sex

All Ages		Under 15		15-34		35-54		55-74		75+	
Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Lung & Bronchus 90,121	Lung & Bronchus 67,509	Brain & ONS 262	Brain & ONS 201	Leukemia 562	Breast 432	Lung & Bronchus 8,571	Breast 9,120	Lung & Bronchus 47,932	Lung & Bronchus 32,970	Lung & Bronchus 33,508	Lung & Bronchus 28,197
Prostate 30,446	Breast 41,514	Leukemia 240	Leukemia 201	Brain & ONS 359	Leukemia 381	Colon & Rectum 3,302	Lung & Bronchus 6,261	Colon & Rectum 12,598	Breast 16,192	Prostate 21,710	Colon & Rectum 16,304
Colon & Rectum 28,471	Colon & Rectum 28,132	Endocrine 95	Endocrine 86	NHL 271	Brain & ONS 239	Liver & IBD 1,919	Colon & Rectum 2,575	Prostate 8,320	Colon & Rectum 9,111	Colon & Rectum 12,375	Breast 15,770
Pancreas 14,876	Pancreas 15,387	Soft Tissue 50	Soft Tissue 45	Colon & Rectum 194	Cervix 225	Pancreas 1,890	Ovary 2,186	Pancreas 7,282	Ovary 6,349	Pancreas 5,673	Pancreas 8,222
Leukemia 12,058	Ovary 14,682	NHL 47	Bone & Joints 43	Bone & Joints 172	NHL 152	Brain & ONS 1,843	Cervix 1,560	Esophagus 5,273	Pancreas 6,010	Leukemia 5,408	Ovary 6,009

Source: National Center for Health Statistics (NCHS) Public -use file for 2002 deaths.
NHL = Non Hodgkin's Lymphoma

Relationship of Cancer to the Leading Causes of Death in the United States

Rank	Cause	Number of Deaths	Age Adjusted Rate*	Percent of Total Deaths
	All Causes	2,443,030	844.6	100.0%
1	Heart Disease	696,900	240.5	28.5%
2	CANCER	557,264	193.5	22.8%
3	Cerebrovascular Diseases	162,669	56.1	6.7%
4	Emphysema, Bronchitis & Asthma	124,809	43.4	5.1%
5	Accidents	106,657	36.9	4.4%
6	Diabetes Mellitus	73,248	25.4	3.0%
7	Pneumonia & Influenza	65,678	22.6	2.7%
8	Alzheimers	58,866	20.2	2.4%
9	Nephritis & Nephrosis	40,974	14.2	1.7%
10	Septicemia	33,862	11.7	1.4%
11	Suicide and Self-Inflicted Injury	31,645	10.9	1.3%
12	Symptoms, Signs and Ill-Defined Conditions	29,866	10.3	1.2%
13	Chronic Liver Dis and Cirrhosis of the Liver	27,253	9.4	1.1%
14	Hypertension without Heart Disease	20,261	7.0	0.8%
15	Homicide and Legal Intervention	17,981	6.2	0.7%
	Other and Ill-Defined	395,097	136.4	16.2%

Source: NCHS Public-use file for 2002 deaths.
* Age adjusted rate per 100,000 Population

Estimated New Cancer Cases and Deaths by Sex for All Races 2005

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Male	Female	Total	Male	Female
All Sites *	1,372,910	710,040	662,870	570,280	295,280	275,000
Oral Cavity and Pharynx	29,370	19,100	10,270	7,320	4,910	2,410
Tongue	7,660	5,050	2,610	1,730	1,120	610
Mouth	10,070	5,370	4,700	1,890	1,100	790
Pharynx	8,590	6,520	2,070	2,130	1,490	640
Other Oral Cavity	3,050	2,160	890	1,570	1,200	370
Digestive System	253,500	134,370	119,130	136,060	75,020	61,040
Esophagus	14,520	11,220	3,300	13,570	10,530	3,040
Stomach	21,860	13,510	8,350	11,550	6,770	4,780
Small Intestine	5,420	2,840	2,580	1,070	580	490
Colon	104,950	48,290	56,660	56,290	28,540	27,750
Rectum	40,340	23,530	16,810			
Anus, Anal Canal, & Anorectum	3,990	1,750	2,240	620	230	390
Liver and Intrahepatic Bile Duct	17,550	12,130	5,420	15,420	10,330	5,090
Gallbladder & Other Biliary	7,480	3,330	4,150	3,340	1,270	2,070
Pancreas	32,180	16,100	16,080	31,800	15,820	15,980
Other Digestive	5,210	1,670	3,540	2,400	950	1,450
Respiratory System	184,800	102,420	82,380	168,140	93,990	74,150
Larynx	9,880	7,920	1,960	3,770	2,960	810
Lung and Bronchus	172,570	93,010	79,560	163,510	90,490	73,020
Other Respiratory	2,350	1,490	860	860	540	320
Bones and Joints	2,570	1,480	1,090	1,210	670	540
Soft Tissues	9,420	5,530	3,890	3,490	1,910	1,580
Skin (excl. basal & squamous)	66,000	37,580	28,420	10,590	6,920	3,670
Melanoma-skin	59,580	33,580	26,000	7,770	4,910	2,860
Other non-epithelial skin	6,420	4,000	2,420	2,820	2,010	810
Breast	212,930	1,690	211,240	40,870	460	40,410
Genital Organs	321,050	241,570	79,480	59,920	31,010	28,910
Cervix Uteri	10,370		10,370	3,710		3,710
Endometrium (uterus)	40,880		40,880	7,310		7,310
Ovary	22,220		22,220	16,210		16,210
Vulva	3,870		3,870	870		870
Vagina and other genital organs, female	2,140		2,140	810		810
Prostate	232,090	232,090		30,350	30,350	
Testis	8,010	8,010		390	390	
Penis and other genital organs, male	1,470	1,470		270	270	
Urinary System	101,880	71,090	30,790	26,590	17,420	9,170
Urinary Bladder	63,210	47,010	16,200	13,180	8,970	4,210
Kidney and Renal Pelvis	36,160	22,490	13,670	12,660	8,020	4,640
Ureter and other urinary organs	2,510	1,590	920	750	430	320
Eye and Orbit	2,120	1,090	1,030	230	110	120
Brain and Other Nervous System	18,500	10,620	7,880	12,760	7,280	5,480
Endocrine Glands	27,650	7,550	20,100	2,370	1,080	1,290
Thyroid	25,690	6,500	19,190	1,490	630	860
Other Endocrine	1,960	1,050	910	880	450	430
Lymphomas and Myelomas	63,740	33,050	30,690	20,610	10,930	9,680
Hodgkin Disease	7,350	3,980	3,370	1,410	780	630
Non-Hodgkin Lymphoma	56,390	29,070	27,320	19,200	10,150	9,050
Multiple Myeloma	15,980	8,600	7,380	11,300	5,660	5,640
Leukemia	34,810	19,640	15,170	22,570	12,540	10,030
Lymphocytic Leukemias	13,700	7,960	5,740	6,090	3,370	2,720
Myeloid Leukemias	16,560	9,170	7,390	9,850	5,470	4,380
Other Leukemias	4,550	2,510	2,040	6,630	3,700	2,930
All Other Sites	28,590	14,660	13,930	46,250	25,370	20,880

Source: Cancer Facts & Figures-2005, American Cancer Society (ACS), Atlanta, Georgia 2005.

Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder.

Incidence projections are based on rates from the NCI SEER Program 1979-2001.

Estimated deaths come from the NCHS public use data file for the total US.

* Estimated deaths for colon & rectum cancers are combined.

The Cost of Cancer

Cancer treatment spending has risen but remains stable in proportion to total U.S. treatment spending.

The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. Cancer treatment accounted for about \$72.0 billion in 2004. This is just under 5 percent of total U.S. spending for medical treatment. The additional economic burden of cancer due to morbidity and premature mortality is estimated to be \$120.4 billion resulting in a total economic burden of cancer in 2004 of \$192.4 billion.

Year	Amount (\$ in millions)	Percent of All Health Care Expenditures
1963	\$1,279	4.35%
1972	3,872	4.96%
1980	13,049	6.01%
1985	18,104	4.81%
1990	27,458	4.46%
1995	41,200	4.69%
2002	60,900	4.57%
2004	72,006	4.67%


Sources:

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller MA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds). *SEER Cancer Statistics Review, 1975-2001*, National Cancer Institute, Bethesda, MD

Brown ML, Riley GF, SchusslerN, Etzioni RD. Estimating health care costs related to cancer treatment from SEER-Medicare data. *Medical care* 2002 Aug; 40 (8 Suppl):IV-104-17.


NHLBI Fact Book - 2003. National Heart, Lung and Blood Institute, Bethesda. Estimates by NHLBI; data from NCHS, HCFA, the Bureau of the Census, and the Institute for Health and Aging, University of California, San Francisco.

**Average Years of Life Lost
Per Person Dying of Cancer
All Races, Both Sexes, 2002**



Source: NCHS public-use data and 2002 life tables.

5 Year Relative Survival Rates by Cancer Site
SEER Program 1995-2001
Males and Females




Data From NCI SEER Program
<http://www.seer.cancer.gov/>

* The relative cumulative rate increased from a prior interval and has been adjusted.
 The 5-year relative survival rate is calculated using 60 monthly intervals.

Cancer Incidence Rates


Annual Percent Changes from 1992 to 2002



* The annual percent change is significantly different from zero ($p < .05$).

Cancer Mortality Rates

Annual Percent Changes from 1992 to 2002



* The annual percent change is significantly different from zero (p<.05).

Cancer Incidence Rates By Race

SEER, 1992-2002

Cancer Site	Incidence Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	526.7	483.5	358.7	339.7	251.9
Males	715.6	572.7	436.0	394.4	285.5
Females	401.6	425.7	311.6	301.2	229.8
Oral Cavity and Pharynx	12.6	11.0	6.7	8.9	7.2
Esophagus	7.6	4.3	3.1	2.9	3.3
Stomach	13.7	7.8	13.6	17.4	10.8
Colon and Rectum	62.6	53.6	39.2	47.0	36.0
Colon excluding Rectum	48.5	38.9	27.0	31.9	25.9
Rectum and Rectosigmoid Junction	14.1	14.7	12.1	15.2	10.1
Liver and IHBD	6.7	4.5	8.9	13.8	7.1
Pancreas	16.0	10.9	10.1	9.3	7.5
Larynx	6.8	4.0	2.8	1.8	1.3
Lung and Bronchus	81.6	63.7	33.6	42.8	36.3
Males	122.8	81.5	47.4	61.2	49.8
Females	53.6	51.3	24.2	28.4	25.8
Melanoma of the Skin	1.0	19.2	4.5	1.5	2.0
Breast (females)	120.2	138.3	88.7	92.8	60.7
<50 years	43.4	43.0	31.8	37.5	21.6
50+ years	321.4	387.8	237.9	237.6	163.0
Cervix Uteri	12.6	9.3	17.3	10.5	6.6
Corpus and Uterus, NOS	18.4	25.9	16.7	17.0	10.1
Ovary	10.3	15.1	11.9	10.4	8.9
Prostate	283.8	175.5	147.0	104.6	63.4
Testis	1.3	6.0	3.4	2.0	2.5
Urinary Bladder	12.5	22.3	11.0	9.7	4.8
Kidney and Renal Pelvis	13.1	11.4	10.8	6.2	11.3
Brain and Other Nervous System	4.0	7.1	5.1	3.5	2.3
Thyroid	3.9	7.0	6.4	8.0	4.1
Hodgkin lymphoma	2.5	2.9	2.4	1.0	0.5
Non-Hodgkin lymphoma	14.4	20.2	16.2	13.7	8.2
All Sites Except Lung and Bronchus	445.1	419.8	325.1	297.0	215.6
Males	592.8	491.2	388.6	333.2	235.7
Females	348.0	374.4	287.4	272.8	203.9

Data source: NCI SEER Program.

NCI's SEER Program, adjusted to the 2000 US population age distribution. Rates for Hispanics exclude cases diagnosed in Alaska, Detroit, Hawaii and Rural Georgia.

^ Statistic not shown. Rate based on less than 25 cases for the time interval.

Cancer Mortality Rates By Race United States, 1992-2002

Cancer Site	Mortality Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	259.3	200.8	137.4	125.1	135.3
Males	360.5	252.5	175.7	155.7	165.5
Females	199.2	167.9	112.1	102.3	115.2
Oral Cavity and Pharynx	4.7	2.8	1.9	2.5	2.3
Esophagus	7.3	4.1	2.4	2.1	2.7
Stomach	9.6	4.4	7.4	9.7	5.5
Colon and Rectum	28.6	21.1	14.2	13.5	13.8
Liver and IHBD	6.0	4.1	7.2	10.8	5.6
Pancreas	14.4	10.3	8.4	7.5	6.2
Larynx	2.9	1.3	1.1	0.5	1.1
Lung and Bronchus	66.9	56.9	25.5	28.6	36.3
Males	109.1	79.3	40.4	41.1	50.0
Females	39.3	41.1	14.9	19.0	26.4
Melanoma of the Skin	0.5	3.0	0.8	0.4	0.7
Breast (females)	36.2	28.0	17.7	12.9	14.4
<50 years	10.9	6.1	4.7	3.9	3.2
50+ years	102.4	85.4	51.7	36.3	43.6
Cervix Uteri	6.2	2.7	3.8	2.9	3.2
Corpus and Uterus, NOS	7.0	3.9	3.2	2.2	2.6
Ovary	7.6	9.3	6.2	4.8	5.1
Prostate	73.7	31.2	24.7	14.1	21.5
Testis	0.2	0.3	0.3	0.1	^
Urinary Bladder	4.0	4.5	2.4	1.9	1.6
Kidney and Renal Pelvis	4.2	4.3	3.8	1.9	4.9
Brain and Other Nervous System	2.7	5.0	2.9	1.9	2.0
Thyroid	0.5	0.5	0.6	0.7	0.3
Hodgkin lymphoma	0.5	0.5	0.5	0.2	0.2
Non-Hodgkin lymphoma	5.7	8.7	6.5	5.2	4.4
All Sites Except Lung and Bronchus	192.4	143.9	111.9	96.5	99.0
Males	251.3	173.1	135.3	114.6	115.5
Females	159.9	126.8	97.2	83.2	88.8

Data source: NCHS public-use data files. Rates for Hispanics exclude cases diagnosed in Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

^ Statistic not shown. Rate based on less than 25 cases for the time interval.

**The Prevalence of Cancer:
Estimated Number of Persons
Diagnosed With Cancer
United States, 2001**

Primary Site	Estimated Prevalence		
	Total [^]	Males	Females
ALL SITES^a	9,809,040	4,321,121	5,487,919
Brain and Central Nervous System	102,006	55,072*	46,934*
Breast (female)	2,210,557	11,163	2,199,394
Cervix	222,001*		222,001*
Colon and Rectum	1,036,691	496,588	540,103
Corpus and Uterus	570,853		570,853
Esophagus	22,366	16,655	5,711
Hodgkin Lymphoma	141,742	74,283	67,459
Kidney and Renal Pelvis	210,994	124,353	86,641
Larynx	99,496	79,743	19,753
Leukemia	180,470	100,769	79,701
Acute Lymphocytic Leukemia	42,330#	23,174#	19,156#
Lung and Bronchus	347,531	175,053	172,478
Melanoma of the Skin	597,811	287,711	310,100
Non-Hodgkin Lymphoma	331,565	171,904	159,661
Oral Cavity and Pharynx	230,697	147,824	82,873
Ovary	167,002		167,002
Pancreas	24,516	11,379	13,137
Prostate	1,727,847	1,727,847	
Stomach	59,199	34,041	25,158
Testis	157,349	157,349	
Thyroid	310,494	71,305	239,189
Urinary Bladder	490,458	361,471	128,987
Childhood (0-19 yrs)	204,131#	104,636#	99,495#

Source: U.S. 2001 cancer prevalence rates are based on 2001 cancer prevalence proportions from the nine SEER registries and 1/1/2001 population estimates based on the average of 2000 and 2001 population estimates from the U.S. Bureau of the Census.

^a The All Sites figures are estimates based on all cancer sites, not just those listed here.

[^] The total column represents prevalence estimates using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). Totals are obtained by summing males and females and not by modeling.

* Completeness index was approximated using empirical data from historical Connecticut tumor registry by age at prevalence

Current methodology does not allow for the estimation of complete prevalence for childhood cancer or acute lymphocytic leukemia. Estimates shown are 25 year limited-duration prevalence.

Fiscal Year 2004 Budget

(Dollars in Thousands)

A. Actual Obligations Resulting From Appropriated Funds:

FY 2004 Appropriation	\$4,770,519
Labor/HHS/ ED Recission	-3,136
Real transfer to other HHS Agencies through .59% Reduction	-28,128
NIH 1% Transfer Assessment	-15,357
Lapse	-5
Actual Obligations Subtotal	4,723,893

B. Reimbursable Obligations:


Reimbursements	12,512
-----------------------	---------------

C. Total NCI Obligations: \$4,736,405 *

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

Program Structure Fiscal Year 2004

(Dollars in Thousands)




Budget Activity	Amount	Percent
Research:		
Cancer Causation	\$1,112,937	23.6%
Detection and Diagnosis Research	335,701	7.1%
Treatment Research	1,092,437	23.1%
Cancer Biology	758,762	16.1%
Subtotal Research	3,299,837	69.9%
Resource Development:		
Cancer Centers Support	410,176	8.7%
Research Manpower Development	173,691	3.7%
Subtotal Resource Development	583,867	12.4%
Cancer Prevention and Control	511,111	10.8%
Program Management and Support	329,078	7.0%
*Total NCI	4,723,893	100.0%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

Extramural Funds Fiscal Year 2004

(Dollars in Thousands)



Mechanism	Amount	Percent
Contracts:		
R&D Contracts	\$298,828	8.1%
Interagency Agreements	79,103	2.2%
Cancer Control Contracts	136,671	3.7%
Construction Contracts	0	0.0%
Subtotal Contracts	514,602	14.0%
Grants:		
Research Project Grants	2,161,359	58.6%
Cancer Centers/SPORES	409,288	11.1%
NRSA	66,264	1.8%
Other Research Grants	314,916	8.5%
Cancer Control Grants	219,965	6.0%
Construction Grants	0	0.0%
Subtotal Grants	3,171,792	86.0%
Total Extramural Funds	3,686,394	100.0%
Total Intramural/RMS/Control Inhouse	1,037,499	
*Total NCI	\$4,723,893	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

NCI Obligations by Mechanism, Fiscal Year 2004

(Dollars in Thousands)

		Number	Amount	% of Total
Research Project Grants	Non-Competing	3,578	\$1,513,234	32.0%
	Administrative Supplements	(311)	54,543	3.6%
	Competing	1,492	494,003	10.5%
	Subtotal, without SBIR/STTR Grants	5,070	2,061,780	43.7%
	SBIR/STTR Grants-R41-44	397	99,579	2.1%
	Subtotal, Research Project Grants	5,467	2,161,359	45.8%
Centers & SPORES	Cancer Centers Grants-P30	61	245,761	5.2%
	SPORES-P20/P50	66	149,366	3.2%
	U54s	18	14,161	0.3%
	Subtotal, Centers	145	409,288	8.7%
Other Research	Career Program			
	Temin & Minority Mentored Awards-K01	113	15,770	0.3%
	Estab. Inv. Award-K05	19	2,396	0.1%
	Preventive Oncology-K07	88	11,393	0.2%
	Clinical Investigator-K08	131	17,243	0.4%
	Clinical Oncology-K12	17	8,791	0.2%
	Transitional Career Development-K22	35	5,333	0.1%
	Mentored Patient Oriented RCDA-K23	61	7,911	0.2%
	Mid-Career Invest. & Patient Orient. Res-K24	25	3,061	0.1%
	Mentored Quant. Res Career-K25	5	712	0.0%
	Inst. Curr. Award-K30	0	1,597	0.0%
	Subtotal, Career Program	494	74,207	1.6%
	Cancer Education Program-R25	101	32,214	0.7%
	Clinical Cooperative Groups-U10	65	154,357	3.3%
	Minority Biomedical Support-S06	0	3,853	0.1%
	Scientific Evaluation-U09/T09	2	10,240	0.2%
	Continuing Education	3	344	0.0%
	Resource Grants-R24/U24	44	26,571	0.6%
	Explor Coop Agreement-U56	40	11,331	0.2%
	Conference Grants-R13	109	1,799	0.0%
Subtotal, Other Research Grants	858	314,916	6.7%	
Subtotal, Research Grants		6,470	2,885,563	61.1%
NRSA Fellowships	<i>Trainees:</i>	1,479	66,264	1.4%
R&D Contracts	R&D Contracts	303	358,248	7.6%
	SBIR Contracts	17	3,321	0.1%
	Subtotal, Contracts	320	361,569	7.7%
Intramural Research	Program	1,971	589,597	12.5%
	NIH Management Fund		119,342	2.5%
	Subtotal, Intramural Research	<i>FTEs:</i> 1,971	708,939	15.0%
RMS	Research Mgmt and Support	676	151,545	3.2%
	NIH Management Fund		20,033	0.4%
	Subtotal, RMS	<i>FTEs:</i> 676	171,578	3.6%
Cancer Prevention and Control	Cancer Control Grants	200	219,965	4.7%
	Cancer Control Contracts	154	153,033	3.2%
	Inhouse	461	145,316	3.1%
	NIH Management Fund		11,666	0.3%
	Subtotal, Prevention and Control	<i>FTEs:</i> 461	529,980	11.2%
Construction				0.0%
*Total NCI	<i>FTEs:</i>	3,108	4,723,893	100.0%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.


Division Obligations by Mechanism, Fiscal Year 2004

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								\$1,454,513	\$58,721
								54,543	
								494,003	
								2,003,059	58,721
								99,579	
								2,102,638	58,721
		3,834					\$241,927		
			\$14,479				134,887		
		5,217	\$1,000				7,944		
		9,051	15,479				384,758		
							15,770		
							2,396		
							11,393		
							17,243		
							8,791		
							5,333		
							7,911		
							3,061		
							712		
							1,597		
							74,207		
							32,214		
								154,357	
								3,853	
								10,240	
								344	
								26,571	
								11,331	
								1,799	
							106,421	208,495	
		9,051	15,479				491,179	2,311,133	58,721
							66,264		
	\$14,597	104,900	3,274	\$29,512			161,525		44,440
	738	1,487	300	290	300		206		
	15,335	106,387	3,574	29,802	300		161,731		44,440
\$379,389	49,228	627					133,405		26,948
379,389	49,228	627					133,405		146,290
		30,380	12,400			\$15,514	69,378		23,873
		30,380	12,400			15,514	69,378		43,906
		20,495		55,506	125,350		18,614		
	5,052	5,457		34,203	84,768		23,553		
4,797	9,618	6,448		29,618	19,130		73,448		2,257
4,797	14,670	32,400		119,327	229,248	0	115,615		13,923
384,186	79,233	178,845	31,453	149,129	229,548	15,514	1,037,572	2,311,133	307,280

NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2004

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$93,493	61.9%
Center for Scientific Review	9,082	6.0%
Center for Information Technology	8,664	5.7%
Service & Supply Fund	13,575	9.0%
Other Research Services	12,487	8.3%
Other OD	13,740	9.1%
*Total Management Fund and SSF	151,041	100.0%
Other NIH Institutes Management Fund	426,379	
Total NIH Management Fund	\$564,290	

*Excludes GSA Rental Payments for Space which totaled \$39,167 in FY 2004

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and followup, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition service, housekeeping services, laundry, and social work

Center for Scientific Review: Initial scientific review of applications, assignment of research grant applications to institutes

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems

GSA Rental Payments for Space: All building rental, including utilities and guard services.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library

Service & Supply Fund: Animal support, collaborative research, conference services, hazardous waste management, interpreting services, library, occupational health and safety, property management support, radiation safety

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

CRADA Receipts Deposited to the U.S. Treasury (Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
1994	1,503	2,272	1,327
1995	2,448	2,811	1,395
1996	3,864	2,017	1,394
1997	4,486	13,378	6,639
1998	11,217	5,351	7,266
1999	9,302	3,645	4,707
2000	8,240	2,717	4,618
2001	6,339	5,295	2,770
2002	8,864	5,048	2,380
2003	11,533	5,221	5,361
2004	11,351	5,213	5,469

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts in NCI and NIH.

Royalty Income Funding History (Dollars in Thousands)

Years	Collections*	Inventor Payments	Other
1994/1995	11,244	1,235	10,009
1995/1996	9,031	953	8,078
1996/1997	13,598	2,175	11,423
1997/1998	9,814	2,321	7,493
1998/1999	22,716	5,084	17,632
1999/2000	21,160	4,695	16,465
2000/2001	37,040	4,811	32,229
2001/2003	27,443	6,210	21,233
2002/2004	42,565	3,961	38,604
2003/2005	27,270	5,799	21,471
2004/2006	26,112	4,757	21,355

* Does not include assessments by NIH.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997 and extended in July 2000 (PL 106-253). This act allows postal customers to contribute to funding for breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service. The Act required the USPS to transfer 70% to NIH and 30% to the DOD of the funds collected above the postage costs and administrative costs. As of November 2004, NCI has received \$28,545,333. NCI has used these funds for research projects directed towards breast cancer research. Thus far, two major programs have been funded -- the "Insight Awards to Stamp Out Breast Cancer" and the "Breast Cancer Research Stamp Exception Program." In FY 2004, 10 Awards for a total of \$3,472K were funded from Breast Cancer Stamp funds.

Funding for Various Research Areas


(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

Disease Area	2000 Actual	2001 Actual	2002 Actual	2003 Actual	2004 Actual
Total NCI Budget	\$3,311.1	\$3,753.7	\$4,176.7	\$4,592.3	\$4,723.9
AIDS	244.1	237.8	254.4	263.4	267.0
Brain & CNS	71.9	80.7	95.2	111.5	132.3
Breast Cancer	438.7	475.2	522.6	548.7	566.2
Cervical Cancer	67.0	72.6	67.6	79.0	79.0
Clinical Trials	614.0	648.6	702.1	799.5	800.0
Colorectal Cancer	175.8	207.4	245.0	261.6	262.0
Head and Neck Cancers	47.0	50.0	58.9	77.7	88.2
Hodgkins Disease	9.4	10.2	11.8	16.5	17.4
Leukemia	141.7	154.0	177.2	200.9	214.7
Liver Cancer	46.2	54.5	62.5	63.7	63.0
Lung Cancer	175.0	206.5	237.5	273.5	276.5
Melanoma	67.9	71.8	82.3	90.7	94.9
Multiple Myeloma	18.0	19.7	20.8	26.3	23.9
Non Hodgkin's Lymphoma	70.4	79.5	85.6	95.2	99.6
Ovarian Cancer	65.5	76.9	93.5	99.4	99.5
Pancreatic Cancer	20.0	21.8	33.1	42.3	52.7
Prostate Cancer	203.2	258.0	278.4	305.2	308.5
Stomach Cancer	8.2	9.0	11.4	13.4	11.6
Uterine Cancer	16.0	18.8	23.1	25.5	27.0

Research Project Grants Number of Awards Fiscal Years 1995 - 2004

Includes Small Business Innovation Research and Small Business Technology Transfer Awards



*EXCLUDES projects awarded with Stamp Out Breast Cancer Funds.

RPGs Requested and Awarded Fiscal Years 1995 - 2004

(Dollars in Thousands)

Fiscal Year	Type	Requested		Awarded		Success Rate	
		No.	Amt.	No.	Amt.		
1995	Competing	New	3,345	\$789,560	645	\$119,760	23.3%
		Renewal	1,048	403,577	375	127,065	
		Supplement	21	7,502	10	1,537	
	Subtotal	4,414	1,200,639	1,030	248,362		
	Non-Competing				2,333	704,374	
	Total				3,363	952,736	
1996	Competing	New	3,071	\$733,313	682	\$142,249	27.5%
		Renewal	947	367,270	422	139,995	
		Supplement	10	1,921	5	694	
	Subtotal	4,028	1,102,504	1,109	282,938		
	Non-Competing				2,381	751,592	
	Total				3,490	1,034,530	
1997	Competing	New	3,328	\$828,653	815	\$160,763	29.2%
		Renewal	815	354,054	392	146,912	
		Supplement	14	3,136	5	755	
	Subtotal	4,157	1,185,843	1,212	308,430		
	Non-Competing				2,532	814,885	
	Total				3,744	1,123,315	
1998	Competing	New	3,054	\$797,477	847	\$189,746	32.8%
		Renewal	697	283,562	382	137,764	
		Supplement	18	4,299	6	1,421	
	Subtotal	3,769	1,085,338	1,235	328,931		
	Non-Competing				2,723	901,845	
	Total				3,958	1,230,776	
1999	Competing	New	3,905	\$1,091,110	1,088	\$237,187	31.8%
		Renewal	757	340,075	390	145,623	
		Supplement	12	3,882	6	2,353	
	Subtotal	4,674	1,435,067	1,484	385,163		
	Non-Competing				2,867	976,610	
	Total				4,351	1,361,773	
2000	Competing	New	4,116	\$1,253,002	957	\$251,628	27.2%
		Renewal	839	435,207	392	175,908	
		Supplement	11	2,379	2	231	
	Subtotal	4,966	1,690,588	1,351	427,767		
	Non-Competing				3,175	1,100,234	
	Total				4,526	1,528,001	
2001	Competing	New	4,342	\$1,374,538	1,050	\$290,707	27.3%
		Renewal	856	437,455	372	173,722	
		Supplement	29	11,108	6	1,214	
	Subtotal	5,227	1,823,101	1,428	465,643		
	Non-Competing				3,267	1,213,098	
	Total				4,695	1,678,741	
2002	Competing	New	4,539	\$1,407,475	1,142	\$302,217	28.4%
		Renewal	861	404,789	384	186,087	
		Supplement	42	8,512	21	3,499	
	Subtotal	5,442	1,820,776	1,547	491,803		
	Non-Competing				3,429	1,356,138	
	Total				4,976	1,847,941	
2003	Competing	New	5,323	\$1,675,039	1,222	\$347,446	26.5%
		Renewal	955	447,122	441	194,084	
		Supplement	20	4,671	5	1,338	
	Subtotal	6,298	2,126,832	1,668	542,868		
	Non-Competing				3,467	1,457,144	
	Total				5,135	2,000,012	
2004	Competing	New	6,558	\$2,045,451	1,333	\$339,925	23.6%
		Renewal	988	518,201	445	210,790	
		Supplement	24	8,337	7	2,196	
	Subtotal	7,570	2,571,989	1,785	552,911		
	Non-Competing				3,682	1,549,727	
	Total				5,467	2,102,638	

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.

Success rate is the number of awarded grants divided by the number of awards requested.

The requested data excludes applications not recommended for further review.


In FY 2004, the total excludes Program Evaluation Dollars at \$58,721. EXCLUDES projects awarded with Stamp Out Breast Cancer Funds.

RPG Awards by Activity Code

Fiscal Years 1995 - 2004*

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	P01	R35	R37	R29	RFA	U01	R03	R21	R33	R15	R55	SBIR/ STTR	TOTAL
1995	#	1,808	149	67	142	342	314	253	44	34			19	191	3,363
	\$	439,122	171,524	63,032	45,125	36,014	72,409	81,771	2,488	7,640			1,126	32,485	952,736
1996	#	1,964	144	65	110	388	268	226	85	46			14	180	3,490
	\$	504,398	182,609	62,550	37,070	41,170	66,102	88,962	5,443	9,599			984	35,643	1,034,530
1997	#	2,194	149	63	90	446	195	169	101	63			21	253	3,744
	\$	583,116	202,317	62,892	30,950	47,413	48,148	81,193	6,411	12,269			1,450	47,156	1,123,315
1998	#	2,454	160	57	75	485	132	157	97	76		2	14	249	3,958
	\$	672,873	228,854	57,712	27,212	52,136	42,750	79,370	6,069	11,782		127	684	51,207	1,230,776
1999	#	2,796	169	38	71	413	261	31	108	159	6	2	6	291	4,351
	\$	775,961	249,583	38,585	27,377	45,361	112,868	21,319	7,355	22,548	2,079	200	620	57,917	1,361,773
2000	#	3,011	179	21	60	314	269	18	100	223	20		5	306	4,526
	\$	898,764	286,234	19,413	24,688	34,769	132,872	13,617	7,034	32,897	10,074	99	450	67,090	1,528,001
2001	#	3,231	178	1	61	210	260	18	122	231	49	3	3	328	4,695
	\$	1,008,199	301,115	2,186	26,682	23,738	150,224	14,873	9,024	42,326	23,883	358	300	75,833	1,678,741
2002	#	3,376	173		65	112	267	17	186	308	79	10	9	374	4,976
	\$	1,093,908	317,632		29,445	12,471	177,195	17,531	14,115	57,633	39,317	1,477	850	86,367	1,847,941
2003	#	3,573	178		70	14	252	27	203	360	81	21		356	5,135
	\$	1,207,387	336,607		35,360	1,584	173,342	31,126	15,207	67,742	37,714	3,086		90,857	2,000,012
2004	#	3,780	177		73	0	233	26	240	425	96	20		397	5,467
	\$	1,277,185	344,489		37,888	53	168,539	31,377	18,067	77,970	42,931	4,560		99,579	2,102,638



*EXCLUDES projects awarded with the Stamp Out Breast Cancer Funds.

Activity Code Descriptions

R01	Research Project (Traditional) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
P01	Research Program Projects broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R35	Outstanding Investigator Grants long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	Method to Extend Research in Time (MERIT) Award long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	First Independent Research Support and Transition (FIRST) Award sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	Request for Applications A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
U01	Research Project (Cooperative Agreement) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
R03	Small Grants research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R21	Exploratory/Developmental Grants Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	Exploratory/Developmental Grants Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R15	Academic Research Enhancement Award (AREA) to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R55	Shannon Awards limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R41	Small Business Technology Transfer (STTR) Grants - Phase I establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R42	Small Business Technology Transfer (STTR) Grants - Phase II establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R43	Small Business Innovation Research (SBIR) Grants - Phase I projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R44	Small Business Innovation Research (SBIR) Grants - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.
U43	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase I utilized when an assistance relationship will exist between the institute and a recipient and in which substantial programmatic involvement is anticipated between the institute and the recipient during performance of the contemplated activity.
U44	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

Cancer Centers by State (P30 Core Grants), Fiscal Year 2004

(Dollars in Thousands)

State	Grantee Institution	Type	Amount
Alabama	University of Alabama at Birmingham	Comprehensive	\$5,525
Arizona	University of Arizona	Comprehensive	3,833
California	Beckman Research Institute	Comprehensive	2,480
	Burnham Institute	Lab/Basic	3,400
	Salk Institute for Biological Sciences	Lab/Basic	2,900
	University of California Davis	Clinical	1,334
	University of California Irvine	Comprehensive	2,599
	University of California Los Angeles	Comprehensive	4,584
	University of California San Diego	Comprehensive	4,179
	University of California San Francisco	Comprehensive	7,145
	University of Southern California	Comprehensive	6,078
Colorado	University of Colorado Health Sciences Center	Comprehensive	3,563
Connecticut	Yale University	Comprehensive	1,039
District of Columbia	Georgetown University	Comprehensive	2,832
Florida	University of South Florida/ H. Lee Moffitt Cancer Center	Comprehensive	2,410
Hawaii	University of Hawaii at Manoa	Clinical	2,125
Illinois	Northwestern University	Comprehensive	4,873
	University of Chicago	Clinical	3,788
Indiana	Indiana University - Purdue University at Indianapolis	Clinical	1,200
	Purdue University West Lafayette	Lab/Basic	1,262
Iowa	University of Iowa	Comprehensive	1,373
Maine	Jackson Laboratory	Lab/Basic	2,775
Maryland	Johns Hopkins University	Comprehensive	5,975
Massachusetts	Dana-Farber Cancer Institute	Comprehensive	10,514
	Massachusetts Institute of Technology	Lab/Basic	2,551
Michigan	University of Michigan at Ann Arbor	Comprehensive	5,184
	Wayne State University	Comprehensive	500
Minnesota	Mayo Clinic Rochester	Comprehensive	5,000
	University of Minnesota Twin Cities	Comprehensive	3,350
Missouri	Washington University	Clinical	4,062
Nebraska	University of Nebraska Medical Center	Clinical	1,522
New Hampshire	Dartmouth College	Comprehensive	2,944
New Jersey	Robert Wood Johnson Medical School	Comprehensive	2,549
New York	American Health Foundation/ Inst for Cancer Prevention	Lab/Basic	2,713
	Cold Spring Harbor Laboratory	Lab/Basic	3,855
	Columbia University Health Sciences	Comprehensive	1,842
	Kaplan Cancer Center/NYU	Clinical	2,575
	Roswell Park Cancer Institute Corp	Comprehensive	3,781
	Sloan-Kettering Institute for Cancer Research	Comprehensive	9,943
Yeshiva University	Clinical	3,928	
North Carolina	Duke University	Comprehensive	5,838
	University of North Carolina Chapel Hill	Comprehensive	5,543
	Wake Forest University	Comprehensive	1,322
Ohio	Case Western Reserve University	Comprehensive	4,318
	Ohio State University	Comprehensive	2,757
Oregon	Oregon Health & Science University	Clinical	1,260
Pennsylvania	Fox Chase Cancer Center	Comprehensive	7,952
	Thomas Jefferson University	Clinical	4,441
	University of Pennsylvania	Comprehensive	5,543
	University of Pittsburgh at Pittsburgh	Comprehensive	4,999
	Wistar Institute	Lab/Basic	2,664
Tennessee	St. Jude Children's Research Hospital	Clinical	4,970
	Vanderbilt University	Comprehensive	5,307
Texas	San Antonio Cancer Institute	Clinical	2,834
	University of Texas M.D. Anderson Cancer Center	Comprehensive	9,497
Utah	Huntsman Cancer Institute/University of Utah	Clinical	800
Vermont	University of Vermont & St. Agric College	Comprehensive	1,348
Virginia	University of Virginia Charlottesville	Clinical	1,065
	Virginia Commonwealth University/Massey Cancer Center	Clinical	1,865
Washington	Fred Hutchinson Cancer Research Center	Comprehensive	9,927
Wisconsin	University of Wisconsin Madison	Comprehensive	5,521
	Total P30s		61 233,854
	Total Planning Grants (P20s)		8,280
	Centers for AIDS Research (CFARs)		3,527
	NCI Co-funded Awards with other NIH Institutes		100

Total Cancer Centers

\$245,761

E-5

Specialized Programs of Research Excellence, Fiscal Year 2004

(Dollars in Thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). This program promotes interdisciplinary research and speeds the bidirectional exchange between basic and clinical science to move basic research findings from the laboratory to applied settings involving patients and populations. The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, and to improve survival, and the quality of life.


Laboratory and clinical scientists work collaboratively to plan, design and implement research programs that impact on cancer prevention, detection, diagnosis, treatment and control. To facilitate this research, each SPORE develops and maintains specialized resources that benefit all scientists working on the specific cancer site, as well as SPORE scientists. An additional SPORE element is a career development program that recruits scientists both within and outside the SPORE institution to enlarge the cadre of laboratory and clinical scientists dedicated to translational research on human cancer. SPOREs meet annually to share data, assess research progress, identify new research opportunities and establish research priorities.

Mechanism	Site	No.	Amount	
P50 SPOREs	Bladder	1	\$2,871	
	Brain	3	6,599	
	Breast	9	24,869	
	Cervical	1	2,450	
	Gastrointestinal	5	10,376	
	Head and Neck	4	6,963	
	Leukemia	1	2,493	
	Lung	6	14,776	
	Lymphoma	3	7,110	
	Melanoma	1	2,322	
	Myeloma	1	2,248	
	Ovarian	3	8,581	
	Pancreatic	1	2,300	
	Prostate	11	28,037	
	Renal	1	2,448	
	Skin	2	5,291	
	Uterine	1	1,949	
	Total P50s		54	131,683
		Lung	1	1,028
	Pancreatic	2	1,802	
Total P20s		3	2,830	
Subtotal		57	134,513	
Co-funded	Urology with NIDDK	0	374	
Total		57	\$134,887	

NRSA Predoctoral and Postdoctoral Trainees


Fiscal Years 1994 - 2004

(Full Time Trainee Positions)



Construction/Renovation Funding Fiscal Years 1994 - 2004

(Dollars in Thousands)



	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
■ Grants	\$15,447	\$6,570	\$1,500	\$1,410	\$1,461	\$958	\$1,488	\$1,500	\$1,500	\$3,000	\$0
■ Contracts	1,002	1,430	1,500	1,590	1,500	2,042	2,012	1,500	3,500	2,000	0
Total	16,449	8,000	3,000	3,000	2,961	3,000	3,500	3,000	5,000	5,000	0

Grant and Contract Awards by State Fiscal Year 2004

(Dollars in Thousands)

State	Grants		Contracts		Total NCI		State
	No	Amount	No	Amount	No	Amount	
Alabama	86	\$41,669	9	\$8,838	95	\$50,507	Alabama
Alaska	3	2,109	0	0	3	2,109	Alaska
Arizona	89	45,742	3	1,504	92	47,246	Arizona
Arkansas	24	8,999	0	0	24	8,999	Arkansas
California	942	475,845	33	31,672	975	507,517	California
Colorado	118	33,129	2	4,845	120	37,974	Colorado
Connecticut	83	27,098	2	3,329	85	30,427	Connecticut
Delaware	7	2,251	0	0	7	2,251	Delaware
District of Columbia	83	30,672	17	10,580	100	41,251	District of Columbia
Florida	144	45,282	3	2,477	147	47,759	Florida
Georgia	72	25,342	9	7,117	81	32,458	Georgia
Hawaii	21	15,789	2	4,905	23	20,694	Hawaii
Illinois	216	90,756	20	9,581	236	100,336	Illinois
Indiana	58	19,127	0	0	58	19,127	Indiana
Iowa	48	16,236	2	4,269	50	20,505	Iowa
Kansas	19	6,567	5	2,961	24	9,527	Kansas
Kentucky	47	13,240	4	3,115	51	16,355	Kentucky
Louisiana	42	10,068	1	1,238	43	11,306	Louisiana
Maine	8	4,453	0	0	8	4,453	Maine
Maryland	248	131,303	69	255,793	317	387,095	Maryland
Massachusetts	657	320,626	8	5,346	665	325,972	Massachusetts
Michigan	225	88,658	8	17,256	233	105,913	Michigan
Minnesota	170	81,004	5	8,783	175	89,787	Minnesota
Mississippi	4	1,132	0	0	4	1,132	Mississippi
Missouri	121	50,892	10	10,194	131	61,086	Missouri
Montana	4	1,043	0	0	4	1,043	Montana
Nebraska	34	12,483	0	0	34	12,483	Nebraska
Nevada	8	2,538	0	0	8	2,538	Nevada
New Hampshire	53	24,717	1	175	54	24,892	New Hampshire
New Jersey	98	34,223	3	3,178	101	37,401	New Jersey
New Mexico	32	12,524	1	1,987	33	14,511	New Mexico
New York	680	289,084	9	8,647	689	297,731	New York
North Carolina	295	120,465	10	3,854	305	124,319	North Carolina
North Dakota	5	1,016	0	0	5	1,016	North Dakota
Ohio	278	96,777	7	4,482	285	101,259	Ohio
Oklahoma	12	3,302	1	118	13	3,419	Oklahoma
Oregon	69	21,781	0	0	69	21,781	Oregon
Pennsylvania	550	297,667	10	9,358	560	307,024	Pennsylvania
Rhode Island	43	15,605	0	0	43	15,605	Rhode Island
South Carolina	55	14,502	0	0	55	14,502	South Carolina
South Dakota	5	3,241	0	0	5	3,241	South Dakota
Tennessee	181	86,925	2	4,220	183	91,145	Tennessee
Texas	476	228,995	10	9,881	486	238,876	Texas
Utah	39	15,752	2	3,506	41	19,258	Utah
Vermont	18	9,404	0	0	18	9,404	Vermont
Virginia	115	33,852	9	14,641	124	48,493	Virginia
Washington	251	133,080	6	6,323	257	139,403	Washington
West Virginia	7	1,430	1	1,688	8	3,119	West Virginia
Wisconsin	112	43,001	4	3,539	116	46,541	Wisconsin
Wyoming	1	48	0	0	1	48	Wyoming
Total	6,956	3,091,445	288	469,397	7,244	3,560,841	Total
Guam	1	483	0	0	1	483	Guam
Puerto Rico	3	2,403	0	0	3	2,403	Puerto Rico
Total	6,960	3,094,331	288	469,397	7,248	3,563,728	Total

Excludes NRSA TAP, Loan Repayment Program, Foreign Contracts and Grants, and Program Evaluation.

Grant and Contract Awards by Country Fiscal Year 2004

(Dollars in Thousands)

Country	Grant		Contract		Total NCI		Country
	No	Amount	No	Amount	No	Amount	
Argentina		\$67				\$67	Argentina
Australia	15	4,069			15	4,069	Australia
Belgium	1	439			1	439	Belgium
Canada	16	7,459	2	\$1,335	18	8,794	Canada
China			1	29	1	29	China
Costa Rica			1	2,934	1	2,934	Costa Rica
Denmark			1	93	1	93	Denmark
Finland			2	668	2	668	Finland
France	6	2,413			6	2,413	France
Germany	1	43			1	43	Germany
Israel	6	969			6	969	Israel
Italy			1	300	1	300	Italy
Mexico		18				18	Mexico
Netherlands	1	107			1	107	Netherlands
Russia			2	185	2	185	Russia
Senegal	1	27			1	27	Senegal
South Africa	1	49			1	49	South Africa
Spain	1	180			1	180	Spain
Sweden	4	547	1	223	5	770	Sweden
Switzerland	1	243			1	243	Switzerland
Taiwan				55		55	Taiwan
United Kingdom	4	756			4	756	United Kingdom
West Indies			1	616	1	616	West Indies
Total Foreign	58	\$17,385	12	\$6,438	70	\$23,823	

Institutions Receiving More than \$15 Million in NCI Support, FY 2004

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$34,456	\$5,477	\$39,933
Arizona	University of Arizona	37,803	1,042	38,845
California	Beckman Research Inst of City of Hope	20,882		20,882
	Burnham Institute	20,713	716	21,429
	National Childhood Cancer Foundation	40,988		40,988
	Science Applications International Corporation		155,284	155,284
	Scripps Research Institute	24,248	1,045	25,293
	Stanford University	35,761		35,761
	University of California System	175,760	2,461	178,221
	University of Southern California	42,804	3,841	46,645
Colorado	University of Colorado Health Sciences Center	20,247	3,945	24,192
Connecticut	Yale University	22,812	1,320	24,132
Dist of Columbia	Georgetown University	20,824	2,097	22,921
Florida	H. Lee Moffitt Cancer Ctr. & Research Institute	17,407		17,407
Georgia	Emory University	15,879	1,874	17,753
Hawaii	University of Hawaii at Manoa	14,281	1,746	16,027
Illinois	Northwestern University	24,593	1,778	26,371
	University of Chicago	35,289	908	36,197
	University of Illinois at Chicago	15,290	1,526	16,816
Indiana	Indiana University-Purdue University at Indianapolis	9,962	5,038	15,000
Iowa	University of Iowa	14,380	4,269	18,649
Maryland	Johns Hopkins University	81,977	1,936	83,913
Massachusetts	Beth Israel Deaconess Medical Center	21,273		21,273
	Brigham & Women's Hospital	34,720		34,720
	Dana-Farber Cancer Institute	75,202		75,202
	Harvard University	36,655		36,655
	Massachusetts General Hospital	41,905	1,601	43,506
	Massachusetts Institute of Technology	19,413		19,413
Michigan	University of Michigan at Ann Arbor	56,287	5,775	62,062
	Wayne State University	13,609	5,513	19,122
Minnesota	Mayo Clinic Rochester	53,334	2,903	56,237
	University of Minnesota Twin Cities	24,035	5,880	29,915
Missouri	Washington University	38,099	8,237	46,336
New Hampshire	Dartmouth College	23,795	175	23,970
New York	Columbia University Health Sciences	24,576		24,576
	Mount Sinai School of Medicine	19,350	25	19,375
	New York University School of Medicine	20,935		20,935
	Roswell Park Cancer Institute Corp	33,338		33,338
	Sloan-Kettering Institute for Cancer Research	61,783	2,935	64,718
	Yeshiva University	28,257		28,257
North Carolina	Duke University	58,906	767	59,673
	University of North Carolina Chapel Hill	41,679	510	42,189
Ohio	Case Western Reserve University	26,373		26,373
	Ohio State University	35,617	343	35,960
Pennsylvania	American College of Radiology	41,003		41,003
	Fox Chase Cancer Center	27,581	4,929	32,510
	NSABP Foundation, Inc.	21,222		21,222
	Thomas Jefferson University	23,076	713	23,789
	University of Pennsylvania	75,453	1,183	76,636
	University of Pittsburgh at Pittsburgh	47,775	2,532	50,307
Tennessee	St. Jude Children's Research Hospital	25,357	2,749	28,106
	Vanderbilt University	53,480		53,480
Texas	Baylor College of Medicine	35,444	155	35,599
	CTRC Research Foundation	30,568		30,568
	University of Texas MD Anderson Cancer Center	107,187	4,621	111,808
Utah	University of Utah	14,791	3,506	18,297
Virginia	University of Virginia Charlottesville	16,710		16,710
Washington	Fred Hutchinson Cancer Research Center	82,125	4,859	86,984
	University of Washington	31,418	8,237	39,655
Wisconsin	University of Wisconsin Madison	33,613	2,229	35,842
	Total	\$2,182,301	\$266,680	\$2,448,981

Includes Manpower Development Grants

Appropriations of the NCI 1938-2004

(In Whole Dollars)

1938 - 1969	\$1,875,699,720	
1970 - 1979	6,073,870,500	
1980 - 1989	11,958,860,000	
1990.....	1,664,000,000	prior to reductions in PL 101-166 (-\$6,839,000) and PL101-239 (-\$22,829,000).
1991.....	1,766,324,000	prior to reductions in PL 101-517 (-\$8,972,000 for salary and expense reduction; -\$42,568,000 for across-the-board reduction).
1992.....	1,989,278,000	prior to reductions in PL 102-170 (-\$21,475,000 for salary and expense reduction; -\$1,262,000 for travel reduction; \$15,000,000 transferred to other institutes for cancer research).
1993.....	2,007,483,000	prior to reductions in PL 102-294 (-\$16,060,000 for .8% reduction to all line items, -\$9,933,000 for S&E reduction, -\$139,000 for consultant services reduction).
1994.....	2,082,267,000	prior to reduction in PL103-211 (-\$5,885,000 administration reduction).
1995.....	2,135,119,000	prior to reductions in PL 103-211 (-\$1,883,000 for Procurement reduction; -\$116,000 for SLUC reduction; -\$1,052,000 for Bonus Pay reduction). Includes \$218,199,000 of AIDS funding.
1996.....	2,251,084,000	Includes \$225,790,000 of AIDS funding.
1997.....	2,382,532,000	Includes \$224,983,000 of AIDS funding.
1998.....	2,547,314,000	prior to reductions in PL 105-119 (-\$4,755,000 via the Secretary's 1% transfer authority). Includes \$8,699,000 transferred via the NIH Director's 1% transfer authority, \$41,000 transfer from U.S. Dept. of State in PL 105-119, and \$226,414,000 of AIDS funding.
1999.....	2,927,187,000	prior to reductions in PL 106-51 (-\$1,940,000 for travel and admin. expenses). Includes -\$931,000 transferred via the Secretary 1% transfer authority, and -\$6,259,000 transferred via the NIH Director's 1% transfer authority, and \$239,190,000 of AIDS funding.
1990 - 1999	21,752,588,000	
2000.....	3,332,317,000	prior to reductions in PL 106-113 (-\$17,763,000 for across the board reduction). Includes \$245,804,000 of AIDS funding.
2001.....	3,757,242,000	prior to reductions in PL 106-554(-\$2,005,000 for across-the-board reduction). Includes -\$711,000 Secretary's 1% transfer, -\$781,000 transfer for Office of Human Research Protection and -\$24,000 lapse. Includes \$255,960,000 of AIDS funding.
2002.....	4,190,405,000	prior to reductions in PL 107-116(-\$4,524,000 via the Secretary's 1% transfer authority, -\$2,054,000 for the enacted rescission, -\$7,118,000 administrative reduction and -\$8,000 lapse). Includes \$254,396,000 of AIDS funding.
2003.....	4,622,394,000	prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and -\$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004.....	4,770,519,000	prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.
1938-2004	62,333,895,220	


By-Pass Budget Requests Fiscal Years 1973-2006

(In Whole Dollars)

Fiscal Year	Request
1973.....	\$550,790,000
1974.....	640,031,000
1975.....	750,000,000
1976.....	898,500,000
1977.....	948,000,000
1978.....	955,000,000
1979.....	1,036,000,000
1980.....	1,055,000,000
1981.....	1,170,000,000
1982.....	1,192,000,000
1983.....	1,197,000,000
1984.....	1,074,000,000
1985.....	1,189,000,000
1986.....	1,460,000,000
1987.....	1,570,000,000
1988.....	1,700,000,000
1989.....	2,080,000,000
1990.....	2,195,000,000
1991.....	2,410,000,000
1992.....	2,612,000,000
1993.....	2,775,000,000
1994.....	3,200,000,000
1995.....	3,600,000,000
1996.....	3,640,000,000
1997.....	2,977,000,000
1998.....	2,702,500,000
1999.....	3,191,000,000
2000.....	3,873,000,000
2001.....	4,135,000,000
2002.....	5,030,000,000
2003.....	5,690,000,000
2004.....	5,986,000,000
2005.....	6,211,000,000
2006.....	6,170,000,000

The National Cancer Act in December 1971, included a provision for the Director, NCI to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

Bypass Requests and Appropriations of the NCI Fiscal Years 1974-2006





Comparison of Dollars, Positions and Space Fiscal Years 1994-2004

Funds are obligations against the annual appropriation in millions of dollars

FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.

The increase in FTEs in FY 2000 is due to the fact that 195 contract staff were converted to NCI appointments.

Space is in thousands of square feet, excluding NCI-Frederick.



**Personnel Resources
Fiscal Years 1995-2004**

Fiscal Year	Full Time Appointment	Part Time Appointment	Training Fellows	Total Personnel Resources
1995	1,767	483	1,055	3,305
1996	1,841	460	960	3,261
1997	1,915	422	1,023	3,360
1998	1,921	466	1,124	3,511
1999	1,941	628	1,060	3,629
2000	2,139	831	1,202	4,172
2001	2,224	912	963	4,099
2002	2,250	979	949	4,178
2003	2,193	1,073	1,191	4,457
2004	2,083	990	1,232	4,305

AIDS Funding History

Fiscal Years 1993-2004

(Dollars in Thousands)

Fiscal Year	NCI	NIH	% NCI of NIH
1993	\$173,029	\$1,073,957	16%
1994	212,868	1,298,996	16%
1995	217,430	1,333,600	16%
1996	225,360	1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%
2004	266,975	2,840,384	9%

